Study on Ficerafusp Alfa and Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent or Metastatic Head and Neck Cancer | Clinical Trial

Study on Ficerafusp Alfa and Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent or Metastatic Head and Neck Cancer | Clinical Trial | Right2Hope